Financial Services
TriplePoint Venture Growth BDC Corp.(TPVG)
Live Price
Offline$5.57
+0.91% today
1Y Change
-25.26%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- $230.00M
- Revenue Growth
- +36.6%
- EPS Growth
- +48.8%
- Dividend Yield
- 18.2%
Coverage: 250 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
TriplePoint Venture Growth BDC Corp. (TPVG) is a Financial Services stock with a market cap of $230.00M and listed on NYSE. The stock last traded around $5.57 and down 25.3% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +36.6%, EPS growth of +48.8%, a dividend yield of 18.2%. What stands out right now is revenue +36.6%, EPS +48.8%, free cash flow -137.3% with operating margin 61.2% and ROIC 6.7%. The dividend matters to the case here, with a current yield around 18.2%. Valuation is more restrained than many high-expectation growth names at P/E 4.6 and price/sales 2.5. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines TPVG price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Financial Services peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+36.6% vs +3.4% peer median
Operating Margin
Above sector median
+61.2% vs +4.7% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 6, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +36.6% and EPS at +48.8%, with operating margin around 61.2%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 18.2%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +3.4% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | โ | +7.0% | +3.0% | -1.8% |
2026 Mar 4, 2026 | -3.9% | +1.7% | -0.4% | -7.0% |
2025 Nov 5, 2025 | -10.3% | +3.4% | +7.4% | +19.9% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TPVG
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TPVG Max Drawdown
-39.35%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TPVG and SPY.
Company Overview
TriplePoint Venture Growth BDC Corp.
New York Stock Exchange
TriplePoint Venture Growth BDC Corp. is a business development company specializing investments in venture capital-backed companies at the growth stage investments. It also provides debt financing to venture growth space companies which includes growth capital loans, secured and customized loans, equipment financings, revolving loans and direct equity investments. The fund seeks to invest in e-commerce, entertainment, technology and life sciences sector. Within technology the areas of focus include: Security, wireless communication equipments, network system and software, business applications software, conferencing equipments/services .big data, cloud computing, data storage, electronics, energy efficiency, hardware, information services, internet and media, networking, semiconductors, software, software as a service, and other technology related subsectors and within life sciences the areas of focus include: biotechnology, bio fuels/bio mass, diagnostic testing and bioinformatics, drug delivery, drug discovery, healthcare information systems, healthcare services, medical, surgical and therapeutic devices, pharmaceuticals and other life science related subsectors. Within growth capital loans it invests between $5 million and $50 million, for equipment financings it invests between $5 million and $25 million, for revolving loans it invests between $1 million and $25 million, and for direct equity investments it may invest between $0.1 million and $5 million (generally not exceeding 5% of the company's total equity). The debt financing products are typically structured as lines of credit and it invests through warrants and secured loans. It targeted returns between 10% and 18%. It does not take board seat in the company.
- Leadership
- James Peter Labe
- IPO Date
- Mar 6, 2014
- Street Address
- 2755 Sand Hill Road
- Mailing
- Menlo Park, CA, 94025
- Region
- Menlo Park, CA, US
- Reporting Currency
- USD
- Investor Line
- 650-854-2090
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 4.6
- EV/EBITDA
- 8.9
- Price/Sales
- 2.5
- Price/Book
- 0.6
Growth
- Revenue
- +36.6%
- EPS
- +48.8%
- Free Cash Flow
- -137.3%
Profitability
- Gross Margin
- 89.0%
- Operating Margin
- 61.2%
- Net Margin
- 54.0%
- ROE
- 14.0%
- ROIC
- 6.7%
Balance Sheet
- Debt/Equity
- 1.33
- Current Ratio
- โ
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.